Skip to main content

Table 2 Comparison of the median overall survival and median time to progression

From: Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis

Study Median OS (month) P Median TTP (month) P
Com Con Com Con
Jiang 2010 [15] 6.2 3.1 < 0.001
Wei 2012 [16] 21.0 10.0 0.006 11.0 6.0 0.001
Ye 2013 [17] 14.8 8.2 0.023 10.3 5.8 0.035
Lencioni 2016 [13] 0.295 24.1 (wks) 23.7 (wks) 0.072
Kudo 2011 [26] 29.7 0.790 5.4 3.7 0.252
  1. Abbreviations: OS overall survival, TTP time to progression, Com combination group, Con control group, and - no description